In January 1997, 62 subjects who had been the placebos dl in the 1995 study were invited to receive the vitamin mineral B12. In June 1997, the 62 placebo subjects were sent a questionnaire bath asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting salts having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the 5. Improvement ratios dl - 12:3 having received treatment, mineral 1:4 not having received treatment.8 A bioequivalence study showed bath that a 3000 mcg lozenge delivered an equivalent salts amount of cyanocobalamin dl to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice mineral daily bath for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 days. Twice daily salts subjects dl maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and mineral antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded on average a greater reduction in bath symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions salts (0.1>p>0.01) dl in total weekly symptom/rescue medication for the active group compared to the placebo for weeks 2, 6, 8 and mineral and bath 9. The results tend to replicate those of the studies on salts injectable cyanocobalamin.10

With no further treatment, the 1996 ten-month follow-up data (n=92) from a high pollen period in Oregon, Washington and Idaho together showed a greater reduction in the active group (n=43) than dl the placebo group (n=49) on the primary endpoint, defined as a combination of symptom and rescue medication scores.8 Patients gave mineral blood serum samples prior to the treatment in 1995 and one year later in 1996. They were bath immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=27) had on average a greater reduction in IgE than the placebo group (n=34) for 13 out of 16 allergens.8

In 1992 in El salts Paso, dl TX a randomized, double-blind, placebo controlled study mineral of subjects (n=130) with allergic rhinitis in 1992-1993 bath was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from salts and dl baseline mineral to Day 30.7 In 1993 in El Paso, bath TX, valid subjects (n=66) returned a second salts set of symptom diaries which dl they had completed for days 365 to 395 (the same period, one year after the first set of symptom diaries). The active group had mean symptom scores showing statistically significant mineral decreases from 1992 to bath 1993. The placebo salts group had increased symptoms in 1993. dl (The mineral relevant pollen counts at the study site in 1993 were much higher bath than salts in 1992, leading to expectation of higher symptoms.)7

©2003 www.female-prenatal-supplements.com All rights reserved.